Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
The Effect of Post-Discharge Multiple Nursing Interventions on the Number of Hospital Admissions, Dyspnea Level, and Quality of Life in COPD Patients Receiving Home Oxygen Therapy: A Randomized Controlled Study
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by persistent airflow obstruction and chronic respiratory symptoms or alpha-1-antitrypsin deficiency in response to inhaled cigarette smoke or other irritants. The excessive morbidity and mortality associated with COPD acute exacerbations represent a significant public health problem that places a high burden on patients, their families and society. In frequent and severe exacerbations, patients may experience a decrease in quality of life, depression, and even death up to one year after hospitalization. Costs associated with COPD are more than $15.5 billion, and hospitalizations and repeated hospital admissions related to acute exacerbations alone account for 70% of all costs. For these reasons, efforts to reduce hospital admissions and hospitalizations associated with recurrent exacerbations are imperative to improve patient's quality of life and reduce the societal burden.
| Status | Recruiting |
| Enrollment | 74 |
| Est. completion date | June 1, 2024 |
| Est. primary completion date | August 15, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Being diagnosed with stage 4 (group D) COPD according to GOLD criteria - Being 18 years or older, - Having a video computer, tablet or phone, - Having an internet connection at home or on the phone, - Residing in the city centre of Konya, - Not having a communication problem, such as an inability to understand/speak Turkish, that would prevent participation in the research, - Being literate, - Using an oxygen concentrator at home. Exclusion Criteria: - Being illiterate, - Being diagnosed with first, second and third-stage COPD according to GOLD criteria, - Having another lung disease in addition to COPD (Lung cancer-Asthma, etc.), - Having physical and/or mental disabilities, - Being visually impaired and/or hearing impaired, - Having a communication problem that prevents participation in the research, such as an inability to understand/speak Turkish, - Having been diagnosed with Covid-19 or having had it in the past, - Having a psychiatric disease |
| Country | Name | City | State |
|---|---|---|---|
| Turkey | Selçuk Tip Fakültesi Hastanesi | Konya |
| Lead Sponsor | Collaborator |
|---|---|
| Necmettin Erbakan University |
Turkey,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | number of hospital admissions | Number of hospital admissions | At the end of the 1st month. | |
| Primary | number of hospital admissions | Number of hospital admissions | At the end of the 3st month. | |
| Primary | number of hospital admissions | Number of hospital admissions | At the end of the 6st month. | |
| Secondary | Scores from the mMRC Dyspnea scale (on the first encounter) | 0 points for no dyspnea (no respiratory distress when moving quickly on a flat surface or climbing a gentle slope);
point for mild dyspnea (difficulty breathing when moving quickly on a flat surface or climbing a gentle slope); points for moderate dyspnea (walks slower than peers when walking on level ground, pauses for breathing); points for severe dyspnea (stopping to breath after walking 100 meters or for a few minutes); and 4 points as very severe dyspnea (shortness of breath while doing daily chores at home, putting on/taking off clothes or going to the toilet). As the score increases, the level of dyspnea also increases. |
At the end of the 1st month. | |
| Secondary | Scores from the mMRC Dyspnea scale (on the first encounter) | 0 points for no dyspnea (no respiratory distress when moving quickly on a flat surface or climbing a gentle slope);
point for mild dyspnea (difficulty breathing when moving quickly on a flat surface or climbing a gentle slope); points for moderate dyspnea (walks slower than peers when walking on level ground, pauses for breathing); points for severe dyspnea (stopping to breath after walking 100 meters or for a few minutes); and 4 points as very severe dyspnea (shortness of breath while doing daily chores at home, putting on/taking off clothes or going to the toilet). As the score increases, the level of dyspnea also increases. |
At the end of the 3st month. | |
| Secondary | Scores from the mMRC Dyspnea scale (on the first encounter) | 0 points for no dyspnea (no respiratory distress when moving quickly on a flat surface or climbing a gentle slope);
point for mild dyspnea (difficulty breathing when moving quickly on a flat surface or climbing a gentle slope); points for moderate dyspnea (walks slower than peers when walking on level ground, pauses for breathing); points for severe dyspnea (stopping to breath after walking 100 meters or for a few minutes); and 4 points as very severe dyspnea (shortness of breath while doing daily chores at home, putting on/taking off clothes or going to the toilet). As the score increases, the level of dyspnea also increases. |
At the end of the 6st month. | |
| Secondary | Scores from the St George Respiratory Questionnaire | The total score that can be obtained from the scale is 0 min. - 100 max. The number zero indicates good health, and the number 100 indicates poor health. The scale is Likert type and the questions are in the form of "yes" and "no".
The symptoms section consists of 8 items and is scored in the range of 0-16 points. The activity section consists of 16 items and is scored in the range of 0-32 points. The effects of the disease section consists of 26 items and is scored in the range of 0-52 points. |
At the end of the 1st month. | |
| Secondary | Scores from the St George Respiratory Questionnaire | The total score that can be obtained from the scale is 0 min. - 100 max. The number zero indicates good health, and the number 100 indicates poor health. The scale is Likert type and the questions are in the form of "yes" and "no".
The symptoms section consists of 8 items and is scored in the range of 0-16 points. The activity section consists of 16 items and is scored in the range of 0-32 points. The effects of the disease section consists of 26 items and is scored in the range of 0-52 points. |
At the end of the 3st month. | |
| Secondary | Scores from the St George Respiratory Questionnaire | The total score that can be obtained from the scale is 0 min. - 100 max. The number zero indicates good health, and the number 100 indicates poor health. The scale is Likert type and the questions are in the form of "yes" and "no".
The symptoms section consists of 8 items and is scored in the range of 0-16 points. The activity section consists of 16 items and is scored in the range of 0-32 points. The effects of the disease section consists of 26 items and is scored in the range of 0-52 points. |
At the end of the 6st month. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
| Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
| Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
| Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
| Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
| Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
| Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
| Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
| Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
| Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
| Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
| Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
| Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
| Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
| Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
| Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|